NCT00384033 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder | Biotech Hunter

Enrollment

638

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Depressive Disorder, Major

Interventions

DRUG

Desvenlafaxine Succinate Sustained-Release (DVS SR)

50 mg tablet, once daily dosing for 8 weeks

DRUG

Desvenlafaxine Succinate Sustained-Release (DVS SR)

100 mg tablet, once daily dosing for 8 weeks

DRUG

Placebo

Matching placebo tablets and capsules, once daily dosing for 8 weeks

DRUG

Duloxetine 60 mg/day

60 mg capsule, once daily dosing for 8 weeks

Trial Locations (22)

19149

Pfizer Investigational Site, Philadelphia

33143

Pfizer Investigational Site, South Miami

33702

Pfizer Investigational Site, St. Petersburg

45408

Pfizer Investigational Site, Dayton

48336

Pfizer Investigational Site, Farmington Hills

48507

Pfizer Investigational Site, Flint

48864

Pfizer Investigational Site, Okemos

53223

Pfizer Investigational Site, Brown Deer

62025

Pfizer Investigational Site, Edwardsville

84107

Pfizer Investigational Site, Salt Lake City

90210

Pfizer Investigational Site, Beverly Hills

90720

Pfizer Investigational Site, Los Alamitos

91105

Pfizer Investigational Site, Pasadena

91316

Pfizer Investigational Site, Encino

91324

Pfizer Investigational Site, Northridge

91506

Pfizer Investigational Site, Burbank

91786

Pfizer Investigational Site, Upland

92660

Pfizer Investigational Site, Newport Beach

92868

Pfizer Investigational Site, Orange

97210

Pfizer Investigational Site, Portland

98104

Pfizer Investigational Site, Seattle

08021

Pfizer Investigational Site, Clementon